The FDA has given the nod to two blood tests for Alzheimer’s disease. On August 20 they cleared C2N’s Precivity AD2 test. On August 24, they announced that Roche’s Elecsys p-tau217 passed muster. Both ...
T lymphocytes have been spotted in the brains of people with Alzheimer’s disease and in mouse models of tauopathy. Now come clues for how those cells are recruited. In the September 3 Nature ...
In a recently developed human brain organoid model, scientists have found a new way APOE4 worsens neuropathology. In the 3 September Cell Stem Cell, Joel Blanchard and colleagues at the Icahn School ...
Loss of myelin, the insulating sheath along nerve fibers, has long been associated with worse cognition and brain health. But could too much myelin be just as bad? In the August 25 Nature Medicine, ...
A cadre of excitatory neurons might underlie synapse loss in the first stages of Alzheimer’s. In the August 26 Nature, scientists led by Won-Suk Chung at the Korea Advanced Institute of Science and ...
Brian Austen, MA; PhD St George's Hospital Medical School Contact Information Brian Austen, MA; PhD LONDON SW17 ORE ...
ALSP, Inc. is developing a small molecule drug for Alzheimer's Disease. As an employee of this company, I have a financial interest in the success of it's drug.
This Notice of Change announces the participation of the National Institute of Neurological Disorders and Stroke (NINDS) in the Notice of Funding Opportunity,"Bioengineering Research Grants (BRG) (R01 ...
This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...
The MAPT haplotypes H1 and H2 are defined by a large inversion polymorphism on chromosome 17. The HI haplotype has been consistently linked to risk for several neurodegenerative diseases, particularly ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results